Show simple item record

2021-11-18Zeitschriftenartikel DOI: 10.3389/fphar.2021.779801
Drug-Drug Interaction Potential, Cytotoxicity, and Reactive Oxygen Species Production of Salix Cortex Extracts Using Human Hepatocyte-Like HepaRG Cells
dc.contributor.authorGomes, João Victor Dutra
dc.contributor.authorHerz, Corinna
dc.contributor.authorHelmig, Simone
dc.contributor.authorFörster, Nadja
dc.contributor.authorMewis, Inga
dc.contributor.authorLamy, Evelyn
dc.date.accessioned2022-01-14T08:16:32Z
dc.date.available2022-01-14T08:16:32Z
dc.date.issued2021-11-18none
dc.date.updated2021-12-02T11:05:27Z
dc.identifier.urihttp://edoc.hu-berlin.de/18452/24571
dc.description.abstractHerbal preparations of willow bark (Salix cortex) are available in many countries as non-prescription medicines for pain and inflammation, and also as dietary supplements. Currently only little information on toxicity and drug interaction potential of the extracts is available. This study now evaluated the effects of two Salix cortex extracts on human hepatocyte-like HepaRG cells, in view of clinically relevant CYP450 enzyme activity modulation, cytotoxicity and production of reactive oxygen species (ROS). Drug metabolism via the CYP450 enzyme system is considered an important parameter for the occurrence of drug-drug interactions, which can lead to toxicity, decreased pharmacological activity, and adverse drug reactions. We evaluated two different bark extracts standardized to 10 mg/ml phenolic content. Herein, extract S6 (S. pentandra, containing 8.15 mg/ml total salicylates and 0.08 mg/ml salicin) and extract B (industrial reference, containing 5.35 mg/ml total salicylates and 2.26 mg/ml salicin) were tested. Both Salix cortex extracts showed no relevant reduction in cell viability or increase in ROS production in hepatocyte-like HepaRG cells. However, they reduced CYP1A2 and CYP3A4 enzyme activity after 48 h at ≥25 μg/ml, this was statistically significant only for S6. CYP2C19 activity inhibition (0.5 h) was also observed at ≥25 μg/ml, mRNA expression inhibition by 48 h treatment with S6 at 25 μg/ml. In conclusion, at higher concentrations, the tested Salix cortex extracts showed a drug interaction potential, but with different potency. Given the high prevalence of polypharmacy, particularly in the elderly with chronic pain, further systematic studies of Salix species of medical interest should be conducted in the future to more accurately determine the risk of potential drug interactions.eng
dc.language.isoengnone
dc.publisherHumboldt-Universität zu Berlin
dc.rights(CC BY 4.0) Attribution 4.0 Internationalger
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectSalix specieseng
dc.subjectwillow barkeng
dc.subjectCYP450 enzymeseng
dc.subjectdrug interactioneng
dc.subjectherb-drug interactioneng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleDrug-Drug Interaction Potential, Cytotoxicity, and Reactive Oxygen Species Production of Salix Cortex Extracts Using Human Hepatocyte-Like HepaRG Cellsnone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:11-110-18452/24571-6
dc.identifier.doi10.3389/fphar.2021.779801none
dc.identifier.doihttp://dx.doi.org/10.18452/23940
dc.type.versionpublishedVersionnone
local.edoc.container-titleFrontiers in pharmacologynone
local.edoc.pages9none
local.edoc.type-nameZeitschriftenartikel
local.edoc.institutionLebenswissenschaftliche Fakultätnone
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-publisher-nameFrontiers Medianone
local.edoc.container-publisher-placeLausannenone
local.edoc.container-volume12none
dc.description.versionPeer Reviewednone
local.edoc.container-articlenumber779801none
dc.identifier.eissn1663-9812

Show simple item record